doi:https://doi.org/

References:

Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018—1022.
Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571—1576.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145—153. [Errata, N Engl J Med 2000;342:748,1376.]
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293—302.
Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782—788.
Neal B., MacMahon S., Chapman N. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955—1964.
Shi Y., Li D., Tardif J.C., Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456—661.
Moreno I., Caballero R., Gonzalez T., et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003;304:862—873.
Gerdts E., Wachtell K., Omvik P., et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan Intervention For Endpoint Reduction in Hypertension trial. Hypertension 2007;49:311—316.
Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J Am Coll Cardiol 2005;45:1832—189.
ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903—1912.
The Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 2009;360:2066—2078.
Sleight P., Redon J., Verdecchia P., et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360—1369.
The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477—1490. [Erratum, N Engl J Med 2010;362:1748.]
The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575—1585.
Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting–enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058—2068.
Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581—588.
Arima H., Hart R.G., Colman S., et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005;36:2164—2169.
Yusuf S., Diener H.-C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225—1237.
Chapman N., Huxley R., Anderson C., et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke 2004;35:116—121.
The GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606—1617. [Erratum, N Engl J Med 2009;360:2379.]
McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767—771.
Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003;362:777—781.
The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174—1183.
Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456—2467.